Last updated on February 2019

A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee


Brief description of study

A study to evaluate safety, tolerability, and pharmacokinetics of a single intra-articular injection of UBX0101 in patients diagnosed with painful osteoarthritis of the knee.

Detailed Study Description

This study is a phase 1, randomized, double-blind, placebo-controlled single ascending dose study that will evaluate safety, tolerability, and pharmacokinetics of UBX0101 in patients diagnosed with painful femoro-tibial osteoarthritis.

Patients will be randomly allocated to receive UBX0101 or placebo in 3:1 randomization by dose level (cohort).

The primary objective is to establish the safety and tolerability of UBX0101 given as a single intra-articular injection into the femoro-tibial joint of patients with osteoarthritis.

Clinical Study Identifier: NCT03513016

Contact Investigators or Research Sites near you

Start Over

Elissa Doens

Well Pharma Medical Research
Miami, FL United States
3.27miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.